Croma-Pharma, a pharmaceutical company, agreed to go public via a SPAC merger with European Healthcare Acquisition & Growth Company, a blank cheque company, for €850m ($902m). “We are pleased to launch an exciting new chapter of Croma‘s growth story. Also, we are proud to join forces with EHC as going public and to thereby also catalyse a significant boost to our global growth potential. We are looking forward to accelerating the roll-out of our clinically and scientifically differentiated portfolio which now spans across a full portfolio including hyaluronic acid solutions as well as toxins. We are excited to combine our expertise with an ideal partner for Croma’s future operational excellence and market expansion. Together, we will build a global leader in aesthetics and reconstructive medicine to the benefit of all our stakeholders," Andreas Prinz, Croma CEO.